Patents by Inventor Robert Gundel

Robert Gundel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T-cell selective interleukin-4 agonists
    Publication number: 20030004314
    Abstract: This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of interleukin 4. Further, the invention is directed to IL-4 muteins having single and double mutations represented by the designators R121E and T13D/R121E, numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
    Type: Application
    Filed: December 29, 2001
    Publication date: January 2, 2003
    Inventors: Armen B. Shanafelt, Jeffrey Greve, Robert Gundel
  • Polynucleotides encoding T-cell selective interleukin-4 agonists
    Patent number: 6433157
    Abstract: The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R121I, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild type IL-4 (His=1).
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: August 13, 2002
    Assignee: Bayer Corporation
    Inventors: Armen B. Shanafelt, Jeffrey Greve, Robert Gundel
  • T-cell selective interleukin-4 agonists
    Patent number: 6335426
    Abstract: This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of interleukin 4. Further, the invention is directed to IL-4 muteins having single and double mutations represented by the designators R121E and T13D/R121E, numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: January 1, 2002
    Assignee: Bayer Corporation
    Inventors: Armen B. Shanafelt, Jeffrey M. Greve, Robert Gundel
  • T-cell selective interleukin-4 agonists
    Patent number: 5986059
    Abstract: The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R1211, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild type IL-4 (His=1).
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: November 16, 1999
    Assignee: Bayer Corporation
    Inventors: Armen B. Shanafelt, Jeffrey Greve, Robert Gundel